Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics (Drug Discovery)

Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics (Drug Discovery)

By: Glenn F. King (editor)Hardback

Up to 2 WeeksUsually despatched within 2 weeks


1. Gives an overview of the development of drugs from peptides and proteins present in venom. 2. Six drugs derived from venoms have already been approved, and there are many more in development. 3. Medicinal chemists, pharmacologists, poisons experts, toxicologists 4. Issues in Toxicology Series, Toxicology Research, MedChemComm 5. The pharmaceutical industry has become increasingly interested in biologics from animal venoms as a potential source for therapeutic agents in recent years, the different aspects of benefit and risk are discussed in this book.

About Author

Professor Glenn King has been working on animal venoms since 1996.He has extensive experience in the discovery, production, and structural and functional characterization of venom proteins, and is intimately aware of the issues surrounding their development as drugs and insecticides. In 2006,Professor King founded an agricultural biotechnology company, Vestaron Corporation, that is developing spider-venom peptides discovered in the lab as bioinsecticides.His current research is largely focussed on the development of venom peptides as analgesics for the treatment of chronic pain.


Venomous animals: evolution and ecology; Chemistry and structural biology of animal venoms; Venoms-based drug discovery: proteomic and transcriptomic approaches; Venoms-based drug discovery: bioassays, high-throughput screens, and target identification; Reptile venoms as a platform for drug development; Cone snail venoms as a platform for drug development; Scorpion venoms as a platform for drug development; Spider-venom peptides as a platform for drug development; Case study 1: development of the analgesic drugs Prialt (R) and Xen2174; Case study 2: development of exenatide for treatment of type 2 diabetes; Case study 3: development of ShK for the treatment of autoimmune diseases; Development of venom natriuretic peptides for treating congestive heart failure; Engineering venom peptides to improve their stability and bioavailability; Manufacturing of venom-derived therapeutic peptides; Venoms to drugs: prospects and pitfalls

Product Details

  • ISBN13: 9781849736633
  • Format: Hardback
  • Number Of Pages: 320
  • ID: 9781849736633
  • weight: 648
  • ISBN10: 1849736634

Delivery Information

  • Saver Delivery: Yes
  • 1st Class Delivery: Yes
  • Courier Delivery: Yes
  • Store Delivery: Yes

Prices are for internet purchases only. Prices and availability in WHSmith Stores may vary significantly